• 1
    Powell IJ. Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol. 2007; 177: 444-449.
  • 2
    Jones BA, Liu WL, Araujo AB, et al. Explaining the race difference in prostate cancer stage at diagnosis. Cancer Epidemiol Biomarkers Prev. 2008; 17: 2825-2834.
  • 3
    Northern Ohio Data & Information Service (NODIS), Maxine Goodman Levin College of Urban Affairs, Cleveland State University. Available at Accessed April 29, 2010.
  • 4
    Smith DS, Carvalhal GF, Mager DE, Bullock AD, Catalona WJ. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol. 1998; 160: 1734-1738.
  • 5
    Saraiya M, Kottiri BJ, Leadbetter S, et al. Total and percent free prostate-specific antigen levels among US men, 2001-2002. Cancer Epidemiol Biomarkers Prev. 2005; 14: 2178-2182.
  • 6
    Moul JW. Population screening for prostate cancer and emerging concepts for young men. Clin Prostate Cancer. 2003; 2: 87-89.
  • 7
    Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst. 2005; 97: 1132-1137.
  • 8
    Ross LE, Berkowitz Z, Ekwueme DU. Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey. CEBP. 2008; 17: 636-644.
  • 9
    Stephenson RA, Smart CR, Mineau GP, James BC, Janerich DT, Dibble RL. The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence–data from the Utah Cancer Registry. Cancer. 1997; 79: 188-190.
  • 10
    Porter CR, Latchamsetty KC, Coogan CL, Kim J. Absence of lower urinary tract symptoms is an independent predictor for cancer at prostate biopsy, but prostate-specific antigen is not: results from a prospective series of 569 patients. Clin Prostate Cancer. 2005; 4: 50-54.
  • 11
    Porter CR, Kim J. Low AUA symptom score independently predicts positive prostate needle biopsy: results from a racially diverse series of 411 patients. Urology. 2004; 63: 90-94.
  • 12
    Latchamsetty KC, Kim J, Porter CR. Prostate specific antigen remains an independent predictor of cancer at prostate biopsy in black American men but not in white men: results from a consecutive series of 914 men. J Urol. 2006; 175( 3 pt 1): 913-917.
  • 13
    Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360: 11320.
  • 14
    Egevad L. Recent trends in Gleason grading of prostate cancer. II. Prognosis, reproducibility and reporting. Anal Quant Cytol Histol. 2008; 30: 254-260.
  • 15
    Kuroiwa K, Uchino H, Yokomizo A, Naito S. Impact of reporting rules of biopsy Gleason score for prostate cancer. J Clin Pathol. 2009; 62: 260-263.
  • 16
    Egevad L, Allsbrook WC, Epstein JI. Current practice of diagnosis and reporting of PIN and glandular atypia among genitourinary pathologists. Mod Pathol. 2006; 19: 180-185.